title: [Streptococcal toxic shock syndrome].
abstract: BACKGROUND
  Streptococcal toxic shock syndrome is now recognized as a toxin-mediated, multisystem illness. It is characterized by an early onset of shock with multiorgan failure and continues to be associated with high morbidity and mortality, caused by group A Streptococcus pyogenes. The symptoms for staphylococcal and streptococcal toxic shock syndrome are similar. Streptococcal toxic shock syndrome was not well described until 1993, when children who had suffered from varicella presented roughly 2-4 weeks later with a clinical syndrome highly suggestive of toxic shock syndrome.
  It is characterized by a sudden onset of fever, chills, vomiting, diarrhea, muscle aches and rash. It can rapidly progress to severe and intractable hypotension and multisystem dysfunction. Almost every organ system can he involved. Complications of streptococcal toxic shock syndrome may include kidney failure, liver failure (and even death. Crystalloids and inotropic agents are used to treat the hypovolemic shock aggressively, with close monitoring of the patient's mean arterial pressure and central venous pressure. An immediate and aggressive management of hypovolemic shock is essential in streptococcal toxic shock syndrome. Targeted antibiotics are indicated: penicillin or a beta-lactam antibiotic is used for treating group A streptococci, and clindamycin has emerged as a key portion of the standard treatment.
authors: Klinika za anesteziju i intenzivnu terapiju, Klinicki centar Vojvodine, Novi Sad. glila@eunet.yu
authors: Ljiljana
authors: L
authors: Gvozdenović
authors: Janko
authors: J
authors: Pasternak
authors: Stanislav
authors: S
authors: Milovanović
authors: Dejan
authors: D
authors: Ivanov
authors: Sasa
authors: S
authors: Milić
mesh_terms: D006801:Humans; D012772:Shock, Septic / Q000175:diagnosis / Q000628:therapy; D013290:Streptococcal Infections / Q000175:diagnosis / Q000628:therapy; D013297:Streptococcus pyogenes